For Patients
Earlier answers, earlier intervention.
What LiverTwin™ means for patients
For the millions living with undiagnosed advanced liver fibrosis, earlier identification means the chance to intervene before cirrhosis, before liver failure, before transplant. LiverTwin transforms a silent, invisible disease into something visible — giving patients a diagnosis, a care plan, and access to emerging therapies like resmetirom while intervention is still possible.
Found before F4
Identifying fibrosis at F2–F3 preserves treatment options — the window where lifestyle change and pharmacotherapy can reverse damage.
Resmetirom eligibility
LiverTwin's care pathway actively surfaces patients who may qualify for approved MASH pharmacotherapy, connecting diagnosis to treatment.
Monitored over time
Longitudinal tracking means fibrosis progression — or regression — is caught early, keeping the care team ahead of the disease curve.